FDA Warns Novo Nordisk Broke Safety Reporting Rules

Follow Drugslib on

By HealthDay Staff HealthDay Reporter

Medically reviewed by Drugs.com. Last updated on March 12, 2026.

via HealthDay

THURSDAY, March 12, 2026 — Federal regulators have warned the maker of Ozempic and Wegovy that it failed to report possible drug side effects to the government.

In a March 5 warning letter, the U.S. Food and Drug Administration (FDA) said Novo Nordisk committed “serious violations” related to safety reporting for semaglutide, the active ingredient in both medications, NBC News reported.

The FDA said the company did not report several serious adverse events, including three deaths among patients taking the drugs, by the legal deadline.

One of the deaths involved a patient who died by suicide, according to the agency. The FDA also said the company failed to investigate or report that case properly.

The agency stressed that the letter does not mean the medications caused the deaths or other side effects.

Instead, the concern involves how quickly the company shared safety information with the agency.

PADE (Postmarketing Adverse Drug Experience) reports are safety reports that drugmakers must send to the FDA after a medicine is approved.

“FDA relies on the complete, accurate and timely submission of PADEs to monitor a product’s safety profile and uphold FDA’s mission to protect and promote public health,” the FDA wrote.

The findings follow an FDA inspection of a Novo Nordisk facility in New Jersey last year.

The agency said the company now has two weeks to explain what steps it will take to prevent violations in the future.

Novo Nordisk said it is already working to fix the issue.

“Novo Nordisk takes PADE reporting requirements seriously and we plan to address the requests in the Warning Letter expeditiously and holistically,” said Anna Windle, head of clinical development, medical and regulatory affairs at the company.

Sources

  • NBC News, March 10, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-03-13 01:48

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords